UNIT 11.12 Functional Characterization of Human Stem Cell–Derived Cardiomyocytes

  1. Glenn E. Kirsch,
  2. Carlos A. Obejero-Paz,
  3. Andrew Bruening-Wright

Published Online: 3 MAR 2014

DOI: 10.1002/0471141755.ph1112s64

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Kirsch, G. E., Obejero-Paz, C. A. and Bruening-Wright, A. 2014. Functional Characterization of Human Stem Cell–Derived Cardiomyocytes. Current Protocols in Pharmacology. 11:11.12:11.12.1–11.12.26.

Author Information

  1. ChanTest Corporation, Cleveland, Ohio

Publication History

  1. Published Online: 3 MAR 2014


Cardiac toxicity is a leading contributor to late stage attrition in the drug discovery process and to withdrawal of approved drugs from the market. In vitro assays that enable earlier and more accurate testing for cardiac risk provide early stage predictive indicators that aid in mitigating risk. Human cardiomyocytes, the most relevant subjects for early stage testing, are severely limited in supply, but human stem cell–derived cardiomyocytes (SC-hCM) are readily available from commercial sources and are increasingly used in academic research, drug discovery, and safety pharmacology. As a result, SC-hCM electrophysiology has become a valuable tool for assessing cardiac risk associated with drug administration. Described in this unit are techniques for recording individual sodium, calcium, and potassium currents, as well as single-cell action potentials and impedance recordings from contracting syncytia of thousands of interconnected cells. Curr. Protoc. Pharmacol. 64:11.12.1-11.12.26. © 2014 by John Wiley & Sons, Inc.


  • stem cell–derived cardiomyocytes;
  • electrophysiology;
  • impedance